JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View

Zacks Investment Research News Agency

2 days ago•Zacks Investment Research

Stocks Medium Importance Neutral

JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View

Jazz Pharmaceuticals tops Q2 sales estimates and raises its 2026 revenue outlook despite an EPS miss, as strong oncology and neuroscience demand lifts shares.

Related Symbols 1

J JAZZ JAZZ

Source: Zacks Investment Research

Visit Source

0 0 0

Comment

Comments

No comments yet

Be the first person to comment on this news item.

Category Stocks

Source Zacks Investment Research

Published 2 days ago

Likes 0

Comments 0

Shares 0

News ID #192

Status Published

This news may have been collected automatically from third-party sources. Please verify important information through the original source and other reliable sources before making any trading or investment decision. This content is provided for informational purposes only and does not constitute financial advice.

Keep comments relevant to the news topic and avoid offensive, promotional, spam, or misleading content.

JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View

Comments

User Menu